Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
J Arthroplasty ; 2022 09 16.
Article in English | MEDLINE | ID: mdl-36122691

ABSTRACT

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

2.
BMC Musculoskelet Disord ; 22(1): 126, 2021 Jan 31.
Article in English | MEDLINE | ID: mdl-33517881

ABSTRACT

BACKGROUND: The role of a tourniquet is still controversial for patients undergoing total knee arthroplasty (TKA). Our current study was performed to determine whether the nonuse of the tourniquet combine with tranexamic acid (TXA) application in TKA patients with end-stage osteoarthritis would accelerate the perioperative recovery rate and provide enough cement mantle thickness for implant fixation. METHODS: In this prospective, randomized controlled trial, 150 end-stage knee osteoarthritis patients receiving TKA were divided into three groups: group A (tourniquet group), group B (non-tourniquet group), and group C (tourniquet in cementation group). All enrolled patients received 3 g of intravenous TXA and 1 g topical TXA. The primary outcomes included blood loss variables and transfusion values. The secondary outcomes included VAS pain score, inflammatory factors level, range of motion, HSS score, postoperative hospital stay, and complication. Furthermore, by using a digital linear tomosynthesis technique, tibial baseplate bone cement mantle thickness was measured in four zones based on the knee society scoring system. RESULTS: No significant difference was found among the three groups with regards to total blood loss, transfusion, and complication. However, patients in group B showed lower inflammatory factors levels, shorter length of hospital stay, better range of motion, and lower postoperative pain. No significant difference was found among the three groups in four zones in terms of bone cement mantle thickness. CONCLUSIONS: For end-stage knee osteoarthritis patients, the absence of tourniquet did not appear to affect blood loss and cement penetration in TKA patients. Furthermore, less inflammation reaction and better knee function can be achieved without a tourniquet. We recommend no longer use a tourniquet in primary TKA for patients with end-stage osteoarthritis when TXA is administrated. TRIAL REGISTRATION: ChiCTR-INR-16009026 . LEVEL OF EVIDENCE: Therapeutic Level I.


Subject(s)
Antifibrinolytic Agents , Arthroplasty, Replacement, Knee , Tranexamic Acid , Arthroplasty, Replacement, Knee/adverse effects , Blood Loss, Surgical/prevention & control , Bone Cements , Humans , Postoperative Hemorrhage , Prospective Studies , Tourniquets
3.
Zhongguo Zhong Yao Za Zhi ; 45(18): 4349-4357, 2020 Sep.
Article in Zh | MEDLINE | ID: mdl-33164362

ABSTRACT

The plants of genus Clinopodium are perennial herbs of Labiatae, which are widely distributed in the world and have a promising medicinal value. Modern researches have shown flavonoids, triterpenoid saponins, terpene glycosides, terpenoids, volatile oils and phenylpropanoids are the main compounds in the plants, presenting various pharmacological effects such as hemostasis, anti-bacteria, anti-inflammation, immunoregulation, reducing blood glucose, antioxidation, and anti-tumor effects. The preparations made of those plants are mainly used for treatment of various bleeding diseases in clinical application. In this review, we systematically summarized the research progress on taxonomy, resource distribution, chemical compositions, pharmacological activities, and clinical application of the medicinal plants of genus Clinopodium. This review provides references and scientific basis for further research and development of genus Clinopodium.


Subject(s)
Lamiaceae , Plants, Medicinal , Flavonoids , Phytochemicals , Plant Extracts
4.
Mediators Inflamm ; 2017: 7960907, 2017.
Article in English | MEDLINE | ID: mdl-29109622

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of lymphoma, with different clinical manifestation and prognosis. The International Prognostic Index (IPI), an index designed during the prerituximab era for aggressive lymphoma, showed variable values in the prediction of patient clinical outcomes. The aim of this study was to analyze the prognostic value and causes of pretreatment liver injury in 363 de novo DLBCL patients in our institution. Pretreatment liver impairment, commonly detected in lymphoma patients, showed significant association with poor outcomes and increased serum inflammatory cytokines in DLBCL patients but had no relation to hepatitis B virus replication nor lymphomatous hepatic infiltration. Multivariate analysis revealed that liver dysfunction, advanced Ann Arbor stage, and elevated lactate dehydrogenase (LDH) were independent adverse prognostic factors of both PFS and OS. Accordingly, a new liver-IPI prognostic model was designed by adding liver injury as an important factor in determining IPI score. Based on Kaplan-Meier curves for PFS and OS, the liver-IPI showed better stratification in DLBCL patients than either the IPI or the revised IPI in survival prediction.


Subject(s)
Liver/injuries , Liver/pathology , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Case-Control Studies , Cyclophosphamide/therapeutic use , Disease-Free Survival , Doxorubicin/therapeutic use , Female , Humans , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Middle Aged , Multivariate Analysis , Prednisone/therapeutic use , Prognosis , Retrospective Studies , Rituximab , Vincristine/therapeutic use
5.
Drug Dev Ind Pharm ; 43(6): 1033-1041, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28279078

ABSTRACT

OBJECTIVE: The objective of this study is to investigate the fate of albumin coupled nanoparticulate system over non-targeted drug carrier in the treatment of hemisectioned spinal cord injury (SCI). SIGNIFICANCE: Targeted delivery of methyl prednisolone (MP) and minocycline (MC) portrayed improved therapeutic efficacy as compared with non-targeted nanoparticles (NPS). METHODS: Albumin coupled, chitosan stabilized, and cationic NPS (albumin-MP + MC - NPS) of poly-(lactide-co-glycolic acid) were prepared using the emulsion solvent evaporation method. Prepared NPS were characterized for drug entrapment efficiency, particle size, poly-dispersity index (PDI), zeta potential, and morphological characteristics. Their evaluation was done based on the pharmaceutical, toxicological, and pharmacological parameters. RESULTS AND DISCUSSION: In vitro release of MP + MC from albumin-MP + MC - NPS and MP + MC - NPS was observed to be very controlled for the period of eight days. Cell viability study portrayed non-toxic nature of the developed NPS. Albumin-MP + MC - NPS showed prominent anti-inflammatory potential as compared with non-targeted NPS (MP + MC - NPS) when studied in LPS-induced inflamed astrocytes. Albumin-MP + MC - NPS reduced lesional volume and improved behavioral outcomes significantly in rats with SCI (hemisectioned injury model) when compared with that of MP + MC - NPS. CONCLUSIONS: Albumin-coupled NPS carrier offered an effective method of SCI treatment following safe co-administration of MP and MC. The in vitro and in vivo effectiveness of MP + MC was improved tremendously when compared with the effectiveness showed by MP + MC - NPS. That could be attributed to the site specific, controlled release of MP + MC to the inflammatory site.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Methylprednisolone/therapeutic use , Minocycline/therapeutic use , Spinal Cord Injuries/drug therapy , Albumins/chemistry , Animals , Astrocytes/drug effects , Behavior, Animal/drug effects , Cell Survival/drug effects , Chitosan/chemistry , Drug Carriers , Drug Combinations , Drug Delivery Systems , Female , Lactic Acid , Nanoparticles , Particle Size , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Rats , Rats, Sprague-Dawley
6.
J Arthroplasty ; 31(2): 438-41, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26515043

ABSTRACT

BACKGROUND: The aim of our study was to investigate the clinical results and serum metal ion levels in a cohort of patients who received total hip arthroplasty (THA) with ceramic-on-metal (CoM) bearings. METHODS: From September 2009 to December 2011, 78 patients (89 hips) who underwent THA with CoM bearings were involved in this study. Harris Hip Score, Short-Form 12, and Western Ontario and McMaster Universities Osteoarthritis Index scores were measured and radiographs were taken for radiographic analysis. Serum metal ion levels of cobalt (Co), chromium (Cr), molybdenum (Mo), and titanium (Ti) were measured using high-resolution inductively coupled plasma-mass spectrometry. RESULTS: Severy-four patients (85 hips) were followed up at a mean of 50 months. At the end of follow-up, HSS, Short-Form 12, and Western Ontario and McMaster Universities Osteoarthritis Index scores were improved significantly compared with preoperative values. No intraoperative and postoperative complications occurred, and no radiolucency, osteolysis, and loosening was found from radiographic examination. Metal ion analysis showed that serum metal ions levels were significantly elevated compared with normal values. Spearman correlation analysis revealed that there was a correlation between 3 metal ion levels and body mass index(Co: r = 0.49, P < .01; Cr: r = 0.47, P < .01; Mo: r = 0.36, P = .04). No correlation was found between metal ion levels and age, cup abduction angle, cup anteversion angle, acetabular version, bilateral arthroplasty, cup screw used, hip stem implant type, or femoral head size. CONCLUSION: Our study concluded that the use of a CoM THA is effective clinically, but the systemic metal ion levels are significantly elevated at midterm follow-up. Whether the elevated metal ion levels will induce an adverse reaction is unknown and long-term follow-up is need.


Subject(s)
Arthroplasty, Replacement, Hip/instrumentation , Hip Prosthesis/adverse effects , Metals/blood , Adult , Aged , Ceramics , Chromium/blood , Cobalt/blood , Female , Femur Head Necrosis/surgery , Follow-Up Studies , Humans , Male , Middle Aged , Molybdenum/blood , Prospective Studies , Prosthesis Design , Titanium/blood , Young Adult
7.
J BUON ; 19(3): 662-6, 2014.
Article in English | MEDLINE | ID: mdl-25261649

ABSTRACT

PURPOSE: To compare the clinicopathological characteristics of patients with occult (OBC) and non-occult breast cancer (non OBC). METHODS: A total of 93 female patients with OBC registered at the First and Second Affiliated Hospitals of Zhejiang Chinese Medical University from January 1980 to December 2005 were included in this retrospective study. Their clinicopathological data were analyzed and compared with those from 1,576 female patients with non OBC, registered during the same time period. RESULTS: The rates of estrogen receptors (ER) and progesterone receptors (PR) in OBC cases were 46.2 and 56.6%, respectively, and 44.1 and 55.6%, respectively (p<0.05). The overall 5- and 10 horbar;year overall survival rates for OBC were 51 and 43%, respectively; the overall 5 horbar;year survival rates for stage 0 horbar;I, stage II and stage III OBC patients were 90, 83 and 52%, respectively, while the overall 10 horbar; year survival rates of the three stage groups were 83, 76 and 42%, respectively. CONCLUSIONS: Compared to non OBC, the ER positive rate of OBC was lower. Furthermore, no significant difference was noticed in 5 horbar; and 10 horbar;year survival rate between OBC and stage III non OBC patients.


Subject(s)
Breast Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Breast Neoplasms/chemistry , Breast Neoplasms/mortality , Female , Humans , Middle Aged , Neoplasm Staging , Receptors, Estrogen/analysis
8.
Aging Dis ; 2024 Feb 22.
Article in English | MEDLINE | ID: mdl-38421827

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with a poor prognosis. To date, more than 40 ALS-related genes have been identified. However, there is still a lack of targeted therapeutic drugs for the treatment of ALS, especially for patients with acute onset and severe disease. A series of studies reported missense heterozygous mutations with loss of function in the coding region of the ANG gene in ALS patients. ANG deficiency is related to the pathogenesis of ALS, but the underlying mechanism has not been determined. This article aimed to synthesize and consolidate the knowledge of the pathological mechanism of ALS induced by ANG mutation and provide a theoretical basis for ALS diagnosis and targeted therapy. This article further delves into the mechanisms underlying the current understanding of the structure and function of the ANG gene, the association between ANG and ALS, and its pathogenesis. Mutations in ANG may lead to the development of ALS through the loss of neuroprotective function, induction of oxidative stress, or inhibition of rRNA synthesis. ANG mutations and genetic and environmental factors may cause disease heterogeneity and more severe disease than in ALS patients with the wild-type gene. Exploring this mechanism is expected to provide a new approach for ALS treatment through increasing ANG expression or angiogenin activity. However, the related study is still in its infancy; therefore, this article also highlights the need for further exploration of the application of ANG gene mutations in clinical trials and animal experiments is needed to achieve improved early diagnosis and treatment of ALS.

9.
Int Urol Nephrol ; 56(2): 483-497, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37740848

ABSTRACT

BACKGROUND: Bladder cancer, predominantly affecting men, is a prevalent malignancy of the urinary system. Although platinum-based chemotherapy has demonstrated certain enhancements in overall survival when compared to surgery alone, the efficacy of treatments is impeded by the unfavorable side effects of conventional chemotherapy medications. Nonetheless, immunotherapy exhibits potential in the treatment of bladder cancer. METHODS: To create an immune-associated prognostic signature for bladder cancer, bioinformatics analyses were performed utilizing The Cancer Genome Atlas (TCGA) database in this study. By identifying differential gene expressions between the high-risk and low-risk groups, a potential therapeutic drug was predicted using the Connectivity Map database. Subsequently, the impact of this drug on the growth of T24 cells was validated through MTT assay and 3D cell culture techniques. RESULTS: The signature included 1 immune-associated LncRNA (NR2F1-AS1) and 16 immune-associated mRNAs (DEFB133, RBP7, PDGFRA, CGB3, PDGFD, SCG2, ADCYAP1R1, OPRL1, PGR, PSMD1, TANK, PRDX1, ADIPOR2, S100A8, AHNAK, EGFR). Based on the assessment of risk scores, the patients were classified into cohorts of low-risk and high-risk individuals. The cohort with low risk demonstrated a considerably higher likelihood of survival in comparison to the group with high risk. Furthermore, variations in immune infiltration were noted among the two categories. Cephaeline, a possible medication, was discovered by analyzing variations in gene expression. It exhibited promise in suppressing the viability and growth of T24 bladder cancer cells. CONCLUSION: The novel predictive pattern allows for efficient categorization of patients with bladder cancer, enabling focused and rigorous treatment for those expected to have a worse prognosis. The discovery of a possible curative medication establishes a basis for forthcoming immunotherapy trials in bladder cancer.


Subject(s)
Urinary Bladder Neoplasms , Male , Humans , Prognosis , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/genetics , Urinary Bladder , Immunotherapy , Cell Culture Techniques
10.
Blood Adv ; 8(7): 1587-1599, 2024 Apr 09.
Article in English | MEDLINE | ID: mdl-38170757

ABSTRACT

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma with clinical and biological heterogeneity. The International Prognostic Index (IPI) shows great prognostic capability in the era of rituximab, but the biological signatures of IPI remain to be discovered. In this study, we analyzed the clinical data in a large cohort of 2592 patients with newly diagnosed DLBCL. Among them, 1233 underwent DNA sequencing for oncogenic mutations, and 487 patients underwent RNA sequencing for lymphoma microenvironment (LME) alterations. Based on IPI scores, patients were categorized into 4 distinct groups, with 5-year overall survival of 41.6%, 55.3%, 71.7%, and 89.7%, respectively. MCD-like subtype was associated with age of >60 years, multiple extranodal involvement, elevated serum lactate dehydrogenase (LDH), and IPI scores ranging from 2 to 5, whereas ST2-like subtype showed an opposite trend. Patients with EZB-like MYC+ and TP53Mut subtypes exhibited poor clinical outcome independent of the IPI; integrating TP53Mut into IPI could better distinguish patients with dismal survival. The EZB-like MYC-, BN2-like, N1-like, and MCD-like subtypes had inferior prognosis in patients with IPI scores of ≥2, indicating necessity for enhanced treatment. Regarding LME categories, the germinal center-like LME was more prevalent in patients with normal LDH and IPI scores of 0 to 1. The mesenchymal LME served as an independent protective factor, whereas the germinal center-like, inflammatory, and depleted LME categories correlated with inferior prognosis for IPI scores of 2 to 5. In summary, our work explored the biological signatures of IPI, thus providing useful rationale for future optimization of the IPI-based treatment strategies with multi-omics information in DLBCL.


Subject(s)
Lymphoma, Large B-Cell, Diffuse , Humans , Middle Aged , Prognosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Rituximab/therapeutic use , Germinal Center/pathology , Tumor Microenvironment
11.
J Urol ; 190(3): 928-34, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23538237

ABSTRACT

PURPOSE: In recent years the orthotopic neobladder has gained increasing popularity in patients who undergo radical cystectomy. However, there are only a few reports of orthotopic neobladders reconstructed from the sigmoid without detubularization. We investigated the complications and functional outcomes of the orthotopic sigmoid neobladder reconstructed using our detaenial technique. MATERIALS AND METHODS: We performed a retrospective study of the detaenial sigmoid neobladder in 210 consecutive patients who underwent radical cystectomy at our institution from January 2003 to March 2010. ANOVA was used to investigate urodynamic finding differentials with time. Univariable and multivariable analyses were done to determine factors influencing continence. RESULTS: Median followup was 48 months. Early complications (90 days or less) were observed in 65 patients (31%). Late complications (greater than 90 days) were observed in 45 patients (21.5%). Five-year daytime and nighttime complete continence rates were 74.6% and 57.1%, respectively. Younger age was the only independent factor associated with complete continence during the day (OR 2.342, 95% CI 1.803-3.041, p <0.001) and night (OR 1.193, 95% CI 1.087-1.310, p <0.001). Mean maximal capacity and post-void residual urine were 328.8 and 22.2 ml, respectively. The mean maximal flow rate was 18.5 ml per second. The mean end filling pressure, pressure at maximal capacity and maximal intravesical pressure were 35.8, 55 and 60.6 cm H2O, respectively. These parameters remained stable with time (each p >0.05). CONCLUSIONS: This study confirms that detaenial sigmoid neobladder is a safe, feasible alternative for urinary diversion.


Subject(s)
Colon, Sigmoid/surgery , Cystectomy/methods , Urinary Bladder Neoplasms/surgery , Urinary Reservoirs, Continent , Adult , Aged , Analysis of Variance , Anastomosis, Surgical/methods , Cohort Studies , Cystectomy/adverse effects , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multivariate Analysis , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Postoperative Complications/physiopathology , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Ureter/surgery , Urethra/surgery , Urinary Bladder Neoplasms/pathology , Urinary Diversion/adverse effects , Urinary Diversion/methods , Urinary Reservoirs, Continent/adverse effects , Urinary Tract Infections/diagnosis , Urinary Tract Infections/epidemiology , Urinary Tract Infections/etiology , Urodynamics
12.
Eur J Pharmacol ; 958: 176071, 2023 Nov 05.
Article in English | MEDLINE | ID: mdl-37741429

ABSTRACT

Pathological cardiac hypertrophy can lead to heart failure, making its prevention crucial. SOX4, a SOX transcription factor, regulates tissue growth and development, although its role in pathological cardiac hypertrophy is unclear. We found that the SOX4 expression was elevated in hypertrophic hearts and angiotensin II (Ang II)-treated neonatal rat cardiomyocytes (NRCMs), and knocking down the SOX4 expression in NRCMs and mouse hearts significantly reduced the hypertrophic response. Mechanistically, SOX4 can bind to the SIRT3 promoter, inhibit SIRT3 transcription and expression, and thus affect downstream MnSOD acetylation levels, leading to abnormal increases in ROS and oxidative stress levels and promoting the occurrence of cardiac hypertrophy. In conclusion, this study identified a new role for SOX4 in regulating cardiac hypertrophy, and decreasing SOX4 expression may be a potential treatment for pathological cardiac hypertrophy.


Subject(s)
Heart Failure , SOXC Transcription Factors , Sirtuin 3 , Animals , Mice , Rats , Angiotensin II/metabolism , Cardiomegaly/metabolism , Heart Failure/pathology , Myocytes, Cardiac/metabolism , Sirtuin 3/metabolism , SOXC Transcription Factors/metabolism
13.
Micromachines (Basel) ; 13(10)2022 Sep 30.
Article in English | MEDLINE | ID: mdl-36295996

ABSTRACT

In order to further improve the degree of frequency response of the surface acoustic wave (SAW) sensor for gas detection, the structure of the forked-finger transducer was analyzed, and its optimal structural parameters were simulated and designed. The simulation model of the unidirectional fork-finger transducer is established by using COMSOL finite element software. The thickness of the piezoelectric substrate, the electrode structure and material, and the thickness of the coating film are optimized and simulated. The results show that: the optimal thickness of the piezoelectric substrate is 3λ. The optimal thickness ratio and the lay-up ratio of the forked-finger electrode are 0.02 and 0.5, respectively. The Al electrode is more suitable as the a forked-finger electrode material compared to Cu, Au and Pt materials. Under the same conditions, the metal oxide-sensitive film (ZnO and TiO2) has a higher frequency response than the polymer-sensitive film (polyisobutylene and polystyrene), and the best sensitive film thickness range is 0.5~1 µm.

14.
Cancer Causes Control ; 22(9): 1289-96, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21744094

ABSTRACT

Several lines of evidence suggest that inflammation may play a role in the etiology of biliary tract cancers. To examine further the role of inflammation, we evaluated the associations between self-reported inflammatory-related medical conditions and the risk of biliary tract cancers in a population-based case-control study in Shanghai, China. Our analysis included 368 gallbladder cancer cases, 191 bile duct cancer cases, 68 ampulla of Vater cancer cases, and 959 healthy subjects. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for biliary tract cancers in relation to six inflammation-related conditions. Gallbladder cancer was significantly associated with cholecystitis occurring at least 5 years prior to interview (OR = 1.7, 95% CI 1.1-2.9). Even though biliary stones did not significantly modify the associations between cholecystitis and gallbladder cancer, 90% of the gallbladder cancer cases with cholecystitis also had biliary stones, indicating that stones likely play an important role in the link between cholecystitis and gallbladder cancer. Among subjects who smoked and drank alcohol, a history of gastric (OR = 4.3, 95% CI 1.2-15.0) or duodenal ulcers (OR = 3.7, 1.2-12.0) was associated with an excess risk of gallbladder cancer. Although the mechanisms are unclear, our results further support the role for inflammation in the etiology of biliary tract cancers.


Subject(s)
Biliary Tract Neoplasms/epidemiology , Gallbladder Neoplasms/epidemiology , Inflammation/epidemiology , Adult , Aged , Alcohol Drinking/epidemiology , Biliary Tract Neoplasms/pathology , Case-Control Studies , China/epidemiology , Cholecystitis/epidemiology , Cholecystitis/pathology , Female , Gallbladder Neoplasms/pathology , Gallstones/epidemiology , Gallstones/pathology , Humans , Inflammation/pathology , Logistic Models , Male , Marijuana Smoking/epidemiology , Middle Aged , Odds Ratio , Risk Factors , Ulcer/epidemiology , Ulcer/pathology
15.
Cancer Cell ; 37(3): 403-419.e6, 2020 03 16.
Article in English | MEDLINE | ID: mdl-32183952

ABSTRACT

Natural killer/T cell lymphoma (NKTCL) is an aggressive and heterogeneous entity of non-Hodgkin lymphoma, strongly associated with Epstein-Barr virus (EBV) infection. To identify molecular subtypes of NKTCL based on genomic structural alterations and EBV sequences, we performed multi-omics study on 128 biopsy samples of newly diagnosed NKTCL and defined three prominent subtypes, which differ significantly in cell of origin, EBV gene expression, transcriptional signatures, and responses to asparaginase-based regimens and targeted therapy. Our findings thus identify molecular networks of EBV-associated pathogenesis and suggest potential clinical strategies on NKTCL.


Subject(s)
Herpesvirus 4, Human/genetics , Lymphoma, T-Cell/genetics , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gene Dosage , Gene Expression Regulation, Neoplastic , Genomics , Humans , Lymphoma, T-Cell/mortality , Lymphoma, T-Cell/pathology , Lymphoma, T-Cell/virology , Molecular Targeted Therapy , Mutation , Natural Killer T-Cells/pathology , Phylogeny , Transcriptome , Whole Genome Sequencing , Xenograft Model Antitumor Assays , Zebrafish
16.
J Arthroplasty ; 24(8): 1184-7, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19195836

ABSTRACT

We evaluated the clinical and radiographic results of 67 (64 patients) cementless Duraloc-300 cups for young active patients after a mean follow-up period of 6.2 years. The preoperative mean Harris hip score improved from 46.24 to 96.5 points at 5 years. The survivorship of the cup, using radiographically confirmed aseptic loosening as the end point, was 100% at 5 years. The mean rate of liner wear was 0.125 mm/y (00-0.39 mm/y). Acetabular osteolysis was found in 14% (9 hips) of the 67 hips, and the osteolysis is related to polyethylene wear (P = .0024) and sex (P = .001). Although there was no aseptic loosening of the components, there was a high rate of liner wear of the polyethylene liner and acetabular osteolysis.


Subject(s)
Arthroplasty, Replacement, Hip/methods , Hip Joint/surgery , Hip Prosthesis , Joint Diseases/surgery , Osteolysis/diagnostic imaging , Acetabulum/surgery , Adult , Arthroplasty, Replacement, Hip/adverse effects , Biocompatible Materials , Female , Follow-Up Studies , Hip Prosthesis/adverse effects , Humans , Male , Middle Aged , Osteolysis/etiology , Polyethylenes , Radiography , Young Adult
17.
Clin Cancer Res ; 25(23): 6995-7003, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31444250

ABSTRACT

PURPOSE: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest. PATIENTS AND METHODS: A phase I, first-in-human, dose-escalation study of anti-CD19 JWCAR029 was conducted in refractory B-NHL (NCT03355859) and 10 patients received CAR T cells at an escalating dose of 2.5 × 107(n = 3), 5 × 107(n = 4), and 1 × 108(n = 3) cells. Core needle biopsy was performed on tumor samples collected from diffuse large B-cell lymphoma patients on Day -6 (1 day before lymphodepletion) and on Day 11 after CAR T-cell infusion when adequate CAR T-cell expansion was detected. RESULTS: The overall response rate was 100%, with 6 of 9 (66.7%) evaluable patients achieving complete remission. The most common adverse events of grade 3 or higher were neutropenia (10/10, 100%), anemia (3/10, 30%), thrombocytopenia (3/10, 30%), and hypofibrinogenemia (2/10, 20%). Grade 1 cytokine release syndrome occurred in all patients and grade 3 neurotoxicity in 1 patient. The average peak levels of peripheral blood CAR T cells and cytokines were similar in 3 different dose levels, but CAR T cells were significantly higher in patients achieved complete remission on Day 29. Meanwhile, RNA sequencing identified gene expression signatures differentially enriched in complete and partial remission patients. Increased tumor-associated macrophage infiltration was negatively associated with remission status. CONCLUSIONS: JWCAR029 was effective and safe in treating refractory B-NHL. The composition of the tumor microenvironment has a potential impact in CAR T therapy response.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD19/chemistry , Immunotherapy, Adoptive/methods , Immunotherapy/methods , Lymphoma, B-Cell/therapy , Neoplasm Recurrence, Local/therapy , Tumor Microenvironment/immunology , Adult , Antigens, CD19/immunology , Combined Modality Therapy , Drug Resistance, Neoplasm , Female , Follow-Up Studies , Humans , Lymphoma, B-Cell/immunology , Lymphoma, B-Cell/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/pathology , Prognosis , Salvage Therapy
18.
Asian J Androl ; 19(6): 655-658, 2017.
Article in English | MEDLINE | ID: mdl-27924790

ABSTRACT

The aim of this study was to determine whether the lower urinary tract storage symptoms of benign prostatic obstruction (BPO) could be completely resolved after plasmakinetic enucleation of the prostate (PKEP) and the possible predictors of persistent symptoms. Two hundred and sixty-seven cases of BPO performed PKEP from July 2008 to June 2009 were retrospectively analyzed. Five-year postoperative data were collected and compared with the preoperative data. According to the urodynamic results, the patients were divided into involuntary detrusor contraction (IDC) group (n = 95) and no IDC group (n = 172) preoperatively; the patients with IDC were divided into IDC-persistent group (n = 33) and IDC-resolved group (n = 62) after PKEP. The predictors of persistent IDC were analyzed. Compared with the preoperative data, the 5-year postoperative data showed that the IDC rate was lower (P = 0.000), Overactive Bladder Symptom Score (OABSS) was lower (P = 0.000), maximum cystometric capacity (MCC) was larger (P = 0.000), Prostate volume (PV) was smaller (P = 0.000), and prostate-specific antigen (PSA) was lower (P = 0.000). Compared with the no IDC group, the IDC group showed that the age was older (P = 0.016), MCC was smaller (P = 0.004), PSA was higher (P = 0.016), and Chronic Inflammation rate was higher (P = 0.004). Compared with IDC-resolved group after PKEP, IDC-persistent group showed that the age was older (P = 0.019), MCC was smaller (P = 0.000), PSA was higher (P = 0.013), and Chronic Inflammation rate was higher (P = 0.032). The present study shows that the storage symptoms are still needed to be focused on after PKEP. The advanced patient age, MCC, PSA, and chronic inflammation may be the important clinical predictors of persistent IDC.


Subject(s)
Lower Urinary Tract Symptoms/surgery , Prostate/surgery , Prostatic Hyperplasia/surgery , Transurethral Resection of Prostate/methods , Aged , Humans , Lower Urinary Tract Symptoms/etiology , Lower Urinary Tract Symptoms/physiopathology , Male , Middle Aged , Prostate/physiopathology , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/physiopathology , Quality of Life , Treatment Outcome , Urodynamics/physiology
20.
J Bone Joint Surg Am ; 98(12): 983-91, 2016 Jun 15.
Article in English | MEDLINE | ID: mdl-27307358

ABSTRACT

BACKGROUND: The use of tranexamic acid (TXA) in primary total hip arthroplasty is well documented. However, considering the potential side effects, including deep vein thrombosis and pulmonary embolism, the ideal method of providing TXA to patients undergoing total hip arthroplasty remains controversial. The objective of this trial was to assess the efficacy and safety of intravenous (IV) administration combined with topical administration of TXA regarding postoperative blood loss and transfusion rates in patients treated with primary unilateral total hip arthroplasty. METHODS: In this prospective, randomized controlled trial, 150 patients were divided into three groups: the combined group (IV administration of 15 mg/kg of TXA combined with topical administration of 1 g/100 mL of TXA), the single IV group (IV administration of 15 mg/kg of TXA), and the placebo group. The primary outcomes included blood-loss variables (total, intraoperative, and drainage blood loss; changes in hemoglobin, hematocrit, and platelet concentration; and amount of IV transfusion fluid) and transfusion values (frequency of transfusion and number of transfused blood units). The secondary outcomes included the length of the hospital stay, range of hip motion, Harris hip score, and prevalences of deep vein thrombosis and pulmonary embolism. RESULTS: The total blood loss in the combined group (mean and standard deviation, 835.49 ± 343.50 mL) was significantly reduced (p < 0.05) in comparison with that in the single IV group (1002.62 ± 366.85 mL) and placebo group (1221.11 ± 386.25 mL). The combined group also had fewer transfusions in comparison with the single IV and placebo groups (1, 8, and 19, respectively; p < 0.05). There was no difference among the 3 groups with regard to the rates of deep vein thrombosis or pulmonary embolism. CONCLUSIONS: Intravenous combined with topical administration of TXA in patients undergoing a primary unilateral total hip arthroplasty significantly reduced postoperative bleeding and the transfusion rate. Studies with more patients and longer follow-up are needed to confirm whether this promising combined strategy is safe with regard to thromboembolic complications. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.


Subject(s)
Antifibrinolytic Agents/therapeutic use , Arthroplasty, Replacement, Hip/methods , Postoperative Hemorrhage/prevention & control , Tranexamic Acid/therapeutic use , Administration, Intravenous , Administration, Topical , Adult , Aged , Antifibrinolytic Agents/administration & dosage , Antifibrinolytic Agents/adverse effects , Female , Humans , Male , Middle Aged , Postoperative Hemorrhage/drug therapy , Pulmonary Embolism/etiology , Tranexamic Acid/administration & dosage , Tranexamic Acid/adverse effects , Treatment Outcome , Venous Thrombosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL